4D Molecular Therapeutics is actively presenting interim and 52-week results from their clinical trials at a prominent scientific conference, highlighting their commitment to advancing innovative ...
EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic ...
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback